Bicara Therapeutics to Present Preclinical Data from Clinical-Stage Bifunctional Antibody Program, BCA101, at AACR Annual Meeting 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it will present preclinical data supporting the ongoing clinical development of the lead investigational candidate BCA101, a bifunctional antibody designed to sequester the immunosuppressive TGF-β in the tumor microenvironment (TME) of EGFR+ tumors, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.

“The preclinical data that will be presented at AACR supports the mechanism of action (MOA) of BCA101, which has demonstrated promising efficacy and a positive safety profile in an ongoing Phase 1/1b clinical trial. Data from in vitro and in vivo studies provides further evidence of BCA101’s potential, as a monotherapy and in combination with anti-PD-1, to induce durable anti-tumor responses in various tumor types, including head and neck cancer, our lead indication,” said Rachel Salazar, SVP of R&D Strategy and Operations of Bicara Therapeutics. “We are also pleased to highlight our collaboration with researchers at the Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute to elucidate the effects of BCA101 on the tumor microenvironment of patients enrolled in the ongoing Ph1/1b clinical trial and highlight the important role of TGF-β neutralization in creating the conditions for an enhanced immune response.”

Details of the presentations are as follows:

Title: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
Presenter: Pradip Nair, Associate Research Director, Syngene International
Presentation Type: Poster
Session Category: Anticancer Immunotherapeutics
Date/Time: Wednesday, April 19, 2023, 9:00 a.m. to 12:30 p.m. ET
Location: Section 22; Abstract #6339

Title: Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment
Presenter: Patrick H. Lizotte, Lead Scientist, Dana-Farber Cancer Institute, Belfer Center for Applied Cancer Science
Presentation Type: Poster
Session Category: Immune Monitoring and Responses to Therapy
Date/Time: Wednesday, April 19, 2023, 9:00 a.m. to 12:30 p.m. ET
Location: Section 39; Abstract #6677

Title: An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies
Presenter: Avanish K. Varshney, Director of Antibody Discovery and Engineering, Bicara Therapeutics
Presentation Type: Poster
Session Category: Therapeutic Antibodies 1
Date/Time: Monday, April 17, 2023, 9:00 a.m. to 12:30 p.m. ET
Location: Section 25; Abstract #1864

All presentations described here will be made available on the Bicara website following the conference.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy. More information is available at www.bicara.com.

Investors
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
212-362-1200

Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936